Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers
Conditions
Interventions
Entinostat
Olaparib
Locations
2
United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Start Date
October 1, 2020
Primary Completion Date
February 4, 2022
Completion Date
February 4, 2022
Last Updated
April 4, 2022
NCT05080946
NCT05281471
NCT04657068
NCT06290193
NCT06855706
NCT04590326
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions